Complexa Inc. Company Profile

22:53 EDT 24th September 2018 | BioPortfolio

Complexa Inc. is a patient-focused, science-driven, clinical stage biopharmaceutical company developing a novel class of compounds, nitrated fatty acids (NFAs), for the safe and effective treatment of debilitating fibrotic and inflammatory diseases. NFAs have demonstrated broad potential to be effective therapeutic agents in multiple disease indications in which oxidative stress, inflammation, fibrosis and/or direct tissue toxicity play significant roles. This class of molecules has the potential to be disease-modifying in many disorders, given their broad activity. An experienced consortium of investors, including Andera Partners, HBM Healthcare Investments, JAFCO, New Enterprise Associates (NEA) and Pfizer Venture Investments have committed funding to advance a platform of NFA agents across multiple orphan disease indications. Complexa’s lead candidate, CXA-10, is currently in Phase 2 development for focal segmental glomerulosclerosis (FSGS) and pulmonary arterial hypertension (PAH). For more information, visit

News Articles [6 Associated News Articles listed on BioPortfolio]

Appointments: News From GSK, DBV Technologies, Complexa, Synlogic And Motif Bio

This week’s announcements include the retirement of GlaxoSmithKline’s CFO, new CEOs at Complexa, Synlogic and Horizon Discovery, and other new...   

Management tracks: Complexa, Immatics

AstraZeneca Q1: Tagrisso Beats Expectations And Drives Oncology Performance

Tagrisso shines for AstraZeneca in the first quarter and the company is on track for approval of a fifth new...   

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have...    

Complexa Appoints Francisco D. Salva Chief Executive Officer and President

-Founder of Acerta Pharma to lead Complexa as it advances Phase 2 clinical development of lead compound CXA-10 in two orphan indications- Complexa Inc., a clinical stage bioph...

First Patient Dosed in the Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat a Rare and Severe Form of Kidney Disease, Focal Segmental Glomerulosclerosis

Complexa Inc. today announced dosing of the first patient in FIRSTx, a Phase 2 clinical trial evaluating the safety and efficacy of the company’s lead candidate, CXA-10, to trea...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]

Complexa, Inc.

Complexa, Inc. is a platform biopharmaceutical company researching and developing endogenous human cell signaling technologies targeting an array of prevalent inflammatory and met...

Complexa Inc.

Complexa Inc. is a patient-focused, science-driven, clinical stage biopharmaceutical company developing a novel class of compounds, nitrated fatty acids (NFAs), for the safe and e...

More Information about "Complexa Inc." on BioPortfolio

We have published hundreds of Complexa Inc. news stories on BioPortfolio along with dozens of Complexa Inc. Clinical Trials and PubMed Articles about Complexa Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Complexa Inc. Companies in our database. You can also find out about relevant Complexa Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topic

Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Corporate Database Quicklinks

Searches Linking to this Company Record